CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D … – Endpoints News
Endpoints News |
CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D …
Endpoints News CRISPR Therapeutics $CRSP and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG, have inked a collaboration agreement with StrideBio to develop AAV vectors for in vivo gene delivery applications. StrideBio's task … Chardan Capital Initiates Coverage on Crispr Therapeutics AG (CRSP) Crispr Therapeutics AG (CRSP) Given Consensus Recommendation of "Strong Buy" by Analysts Moody's (MCO) Reaches $114.33 52-Week High, Crispr Therapeutics AG (CRSP) SI Decreased By 6.79% |
